Abstract 5016
Background
Checkpoint inhibition as monotherapy has limited success in advanced metastatic epithelial ovarian cancer (epOC) and strategies to increase immunogenicity are needed. Pegilodecakin (AM0010) is a pegylated recombinant human interleukin-10 that stimulates activation, survival and clonal expansion of intra-tumoral, tumor antigen specific CD8+ T cells. Pegilodecakin also up-regulates IFNγ and expression of MHC, which enables tumor antigen presentation in neoplasias of low mutational burden (eg, epOC) and promotes immunosurveillance by expanding effector memory T cells (Mumm et al 2010, 2011). Pegilodecakin reduces tumor inflammatory processes such as angiogenesis and metastatic dissemination (Oft 2017), the off-target auto-immune side effects of immunotherapy and the inflammatory-related side effects of some chemotherapies. Preclinical data suggest synergy of pegilodecakin in reducing tumor volume when combined with platinum/taxane based chemotherapy.
Methods
In a 353 pt phase 1/1b dose escalation and expansion study conducted in the US (2013-2017), 12 platinum-refractory, heavily pretreated epOC pts received daily pegilodecakin alone (N = 9) or in combination with platinum/taxane-based chemotherapy (N = 3). Responses were assessed by irRC.
Results
In monotherapy 4 (44%) had a PFS of more than 3.5 months and a survival of more than 14.7 months. No IRAEs were seen. G3/4 TrAEs in monotherapy: anemia (33%), fatigue (33%), thrombocytopenia (22%); in platinum/taxane combo: anemia (33%), diarrhea (33%), neutropenia (33%), thrombocytopenia (33%).Table: 1146P
| Pegilodecakin | N | Prior Therapies | ORR | DCR | mPFS | mOS |
|---|---|---|---|---|---|---|
| Regimen | E (ITT)3 | Median (Range) | % | % | mos | mos |
| Monotherapy1 | 9 (9) | 5 (4-11) | - | 66.7 | 2.4 | 13.8 |
| Plus Chemotherapy2 | 3 (3) | 2 (1-7) | - | 66.7 | 5.2 | 10.7 |
1.0 or 20 µg/kg;
2Pegilodecakin 10 µg/kg + Carboplatin + Paclitaxel or Pegilodecakin 10 µg/kg + Cisplatin + Paclitaxel or Pegilodecakin 2.5 µg/kg + Carboplatin + Docetaxel;
3E (evaluable - baseline tumor assessment + >1 post-baseline assessments, and no major protocol deviations); ITT (intent to treat); Data cut on 05.01.18.
Conclusions
Pegilodecakin alone demonstrated durable disease control with manageable toxicity in a proportion of treatment refractory epOC pts. Preliminary findings in a small subset of epOC pts who received pegilodecakin in combination with platinum plus taxane-based chemotherapy yielded promising results.
Clinical trial identification
NCT02009449.
Legal entity responsible for the study
ARMO BioSciences.
Funding
ARMO BioSciences.
Editorial Acknowledgement
Disclosure
A. Hung, M. Oft, J. Leveque: Employee: ARMO BioSciences. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract